StysPKZamponiGWVan MinnenJ. Will the real multiple sclerosis please stand up?Nat Rev Neurosci2012; 13: 507–514.
2.
GovermanJ. Autoimmune T-cell responses in the central nervous system. Nat Rev Immunol2009; 9: 393–407.
3.
Van NoortJMVandenElsenPJVan HorssenJ. Preactive multiple sclerosis lesions offer novel clues for neuroprotective therapeutic strategies. CNS Neurolog Disord Drug Targ2011; 10: 68–81.
4.
KyewskiBKleinL. A central role for central tolerance. Annu Rev Immunol2006; 24: 571–606.
5.
KebirHIferganIAlvarezJI. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Annals Neurol2009; 66: 390–402.
6.
LowtherDEChongDLAscoughS. Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T-cell response. Acta Neuropathol2013; 126: 501–515.
7.
PanitchHSHirschRLHaleyAS. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet1987; 1: 893–895.
8.
PopkoBCorbinJGBaerwaldKD. The effects of interferon-gamma on the central nervous system. Mol Neurobiol1997; 14: 19–35.
9.
NavesRSinghSPCashmanKS. The interdependent, overlapping, and differential roles of Type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol2013; 191: 2967–2977.
10.
SkurkovichSBoikoABeliaevaI. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult Scler2001; 7: 277–284.
